Loading...
XSTOAROC
Market cap7mUSD
Dec 23, Last price  
0.38SEK
1D
0.00%
1Q
-26.86%
Jan 2017
-94.51%
IPO
-89.77%
Name

AroCell AB (publ)

Chart & Performance

D1W1MN
XSTO:AROC chart
P/E
—
P/S
2.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
41.40%
Rev. gr., 5y
122.92%
Revenues
43m
+16.37%
26,8540000460,21754,606502,033781,841442,69784,00011,996,00036,986,00043,039,000
Net income
-59m
L+0.55%
-2,152,234-3,584,151-3,156,941-3,732,929-6,368,852-7,478,995-9,234,943-17,270,758-20,757,029-16,201,966-19,459,000-50,026,000-58,973,000-59,297,000
CFO
-13m
L-1.88%
-2,593,000000-9,127,552-7,167,532-15,235,183-16,407,394-15,055,220-18,902,000-28,206,000-13,694,000-13,436,000

Profile

AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.
URL
https://arocell.com/
IPO date
May 25, 2011
Employees
26
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
43,039
16.37%
36,986
208.32%
11,996
14,180.95%
Cost of revenue
103,453
99,339
62,868
Unusual Expense (Income)
NOPBT
(60,414)
(62,353)
(50,872)
NOPBT Margin
Operating Taxes
(326)
(547)
Tax Rate
NOPAT
(60,414)
(62,027)
(50,325)
Net income
(59,297)
0.55%
(58,973)
17.88%
(50,026)
157.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
250
81,811
BB yield
-0.25%
-61.27%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
6,124
Net debt
(50,723)
(65,189)
(18,402)
Cash flow
Cash from operating activities
(13,436)
(13,694)
(28,206)
CAPEX
(1,279)
(4,058)
(370)
Cash from investing activities
(1,280)
(10,117)
4,544
Cash from financing activities
250
70,598
FCF
(58,132)
(65,763)
(54,208)
Balance
Cash
50,723
65,189
18,402
Long term investments
Excess cash
48,571
63,340
17,802
Stockholders' equity
(277,361)
(218,064)
(159,281)
Invested Capital
441,007
440,758
376,736
ROIC
ROCE
EV
Common stock shares outstanding
230,361
215,354
96,153
Price
0.44
-29.52%
0.62
-34.74%
0.95
-59.40%
Market cap
100,668
-24.60%
133,519
46.17%
91,346
-47.96%
EV
49,945
68,330
76,876
EBITDA
(14,877)
(15,171)
(46,080)
EV/EBITDA
Interest
13
5
1,000
Interest/NOPBT